ClinicalTrials.Veeva

Menu

Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Advanced Prostate Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT00871585
NIS-OHR-CAS-2008/1

Details and patient eligibility

About

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.

Enrollment

340 patients

Sex

Male

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with diagnosis of advanced prostate cancer
  • Patients who are already treated with bicalutamide for at least 4 weeks and maximum 12 weeks
  • Patients capable of signing ICF

Exclusion criteria

  • Patients with hypersensitivity to bicalutamide
  • Patients on therapy with terfenadin, astemizol or cisapride
  • Participation in a clinical study during the last 30 days

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems